Literature DB >> 17310039

Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies.

K Hara1, T Mashima, A Matsuda, K Tanaka, M Tomita, H Shiraishi, M Motomura, M Nishizawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17310039     DOI： 10.1212/01.wnl.0000254617.15644.f4

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 2.  Recommendations of the Neurolaryngology Study Group on laryngeal electromyography.

Authors:  Andrew Blitzer; Roger L Crumley; Seth H Dailey; Charles N Ford; Mary Kay Floeter; Allen D Hillel; Henry T Hoffmann; Christy L Ludlow; Albert Merati; Michael C Munin; Lawrence R Robinson; Clark Rosen; Keith G Saxon; Lucian Sulica; Susan L Thibeault; Ingo Titze; Peak Woo; Gayle E Woodson
Journal:  Otolaryngol Head Neck Surg       Date:  2009-04-09       Impact factor: 3.497

3.  Vocal cord palsy: An uncommon presenting feature of myasthenia gravis.

Authors:  Prahlad K Sethi; Anuradha Batra; Nitin K Sethi; Josh Torgovnick; Edward Arsura
Journal:  Ann Indian Acad Neurol       Date:  2011-01       Impact factor: 1.383

4.  Pneumonia and hypercapnic respiratory failure.

Authors:  Gusts Ancans; Dace Zentina; Zaiga Kravale
Journal:  Breathe (Sheff)       Date:  2019-09

5.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

6.  Bilateral Vocal Fold Paralysis in Myasthenia Gravis: A Case Report and Literature Review.

Authors:  Christopher Nelke; Bendix Labeit; Sven G Meuth; Tobias Warnecke; Rainer Dziewas; Tobias Ruck
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.